Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.20381/ruor-4738
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world.

  2012cited by this paper
• Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.

  2011cited by this paper
• Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.

  2011cited by this paper
• Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

  2011cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

  2011cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment

  2011cited by this paper
• Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

  2011cited by this paper
• Estimating the Power of Indirect Comparisons: A Simulation Study

  2011cited by this paper
• Targeting of adenosine receptors in ischemia–reperfusion injury

  2011cited by this paper
• High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction.

  2011cited by this paper
• Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor

  2011cited by this paper
• Aspirin Dose and Ticagrelor Benefit in PLATO: Fact or Fiction?

  2011cited by this paper
• Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified

  2011cited by this paper
• Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.

  2011cited by this paper
• Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry

  2011cited by this paper
• Explaining the unexpected: Insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel

  2011influential reference
• ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

  2010cited by this paper
• Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function

  2010cited by this paper
• Ticagrelor for the treatment of arterial thrombosis

  2010cited by this paper
• Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.

  2010cited by this paper
• Antiplatelet therapies for the treatment of cardiovascular disease

  2010influential reference
• Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

  2010cited by this paper
• Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

  2010cited by this paper
• Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.

  2010cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• The role of antiplatelet therapy in the secondary prevention of coronary artery disease

  2010cited by this paper
• Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

  2010cited by this paper
• Cardioprotection With Adenosine-Regulating Agent, GP531: Effects on No-Reflow, Infarct Size, and Blood Flow Following Ischemia/ Reperfusion in the Rabbit

  2010cited by this paper
• Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.

  2010cited by this paper
• Elinogrel: pharmacological principles, preclinical and early phase clinical testing.

  2010cited by this paper
• Meta-analysis as the core of evidence-based behavioral medicine: tools and pitfalls of a statistical approach

  2010cited by this paper
• Comparison of efficacy of antiplatelet treatments for patients with claudication

  2010cited by this paper
• Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010

  2010cited by this paper
• Left ventricular remodeling after primary percutaneous coronary intervention.

  2010cited by this paper
• The PLATO trial: do you believe in magic?

  2010cited by this paper
• Examining biology and pharmacology-based hypotheses in the PLATO trial

  2010cited by this paper
• Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

  2010cited by this paper
• Ticagrelor in ACS: redefining a new standard of care?

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Mortality in the TRITON trial: update from the FDA prasugrel action package.

  2010cited by this paper
• Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.

  2010influential reference
• The case for routine genotyping in dual-antiplatelet therapy.

  2010cited by this paper
• Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.

  2010cited by this paper
• New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.

  2010cited by this paper
• Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans

  2010cited by this paper
• Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

  2010cited by this paper
• Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.

  2010cited by this paper
• Evaluating novel agent effects in multiple‐treatments meta‐regression

  2010cited by this paper
• Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.

  2010cited by this paper
• Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

  2010cited by this paper
• Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study

  2010cited by this paper
• Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

  2009cited by this paper
• Genetic determinants of response to clopidogrel and cardiovascular events.

  2009cited by this paper
• Platelet inhibition with cangrelor in patients undergoing PCI.

  2009cited by this paper
• Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.

  2009cited by this paper
• Reperfusion Injury, Microvascular Dysfunction, and Cardioprotection: The “Dark Side” of Reperfusion

  2009cited by this paper
• Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.

  2009cited by this paper
• Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry.

  2009cited by this paper
• Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?

  2009cited by this paper
• Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison

  2009cited by this paper
• Adenosine: An Old Drug Newly Discovered

  2009cited by this paper
• The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.

  2009cited by this paper
• The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.

  2009cited by this paper
• Cangrelor: a review on its mechanism of action and clinical development

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009influential reference
• Weighing benefits and risks--the FDA's review of prasugrel.

  2009cited by this paper
• Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

  2009cited by this paper
• Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews

  2009cited by this paper
• Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

  2009influential reference
• Prasugrel: A Critical Comparison with Clopidogrel

  2009cited by this paper
• The FDA Prasugrel Review: Adjudication of Myocardial Infarction Controversy

  2009cited by this paper
• Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis

  2009cited by this paper
• Prasugrel compared with high-dose clopidogrel in acute coronary syndrome

  2009cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2009cited by this paper
• Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses

  2009cited by this paper
• Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

  2009cited by this paper
• National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004

  2009cited by this paper
• Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

  2009cited by this paper
• Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist

  2009cited by this paper
• Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors

  2009cited by this paper
• Intravenous platelet blockade with cangrelor during PCI.

  2009cited by this paper
• Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

  2009cited by this paper
• Canadian Agency for Drugs and Technologies in Health

  2009cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  2009cited by this paper
• Faculty Opinions recommendation of Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction

  2009cited by this paper
• Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation

  2009cited by this paper
• Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update

  2009cited by this paper
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

  2009cited by this paper
• A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered.

  2009cited by this paper
• Impact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Systematic Review

  2008cited by this paper
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.

  2008cited by this paper
• A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.

  2008cited by this paper
• Bleeding risks of combination vs. single antiplatelet therapy: a meta‐analysis of 18 randomized trials comprising 129 314 patients

  2008cited by this paper
• Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

  2008cited by this paper
• Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

  2008cited by this paper
• Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials.

  2008cited by this paper
• Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.

  2008cited by this paper

• No citing papers are available for this paper.